163 related articles for article (PubMed ID: 36344179)
1. Molecular Genetics of Prostate Cancer and Role of Genomic Testing.
Akhoundova D; Feng FY; Pritchard CC; Rubin MA
Surg Pathol Clin; 2022 Dec; 15(4):617-628. PubMed ID: 36344179
[TBL] [Abstract][Full Text] [Related]
2. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitor Insensitivity to
Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
[TBL] [Abstract][Full Text] [Related]
4. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing in Prostate Cancer.
Sokolova AO; Cheng HH
Curr Oncol Rep; 2020 Jan; 22(1):5. PubMed ID: 31974718
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
8. Germline Testing in Prostate Cancer: When and Who to Test.
Sokolova A; Cheng H
Oncology (Williston Park); 2021 Oct; 35(10):645-653. PubMed ID: 34669358
[TBL] [Abstract][Full Text] [Related]
9. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
10. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Dhawan M; Ryan CJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
[TBL] [Abstract][Full Text] [Related]
11. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair.
Herberts C; Wyatt AW; Nguyen PL; Cheng HH
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390384. PubMed ID: 37207301
[TBL] [Abstract][Full Text] [Related]
15. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
18. Acting on Actionable Mutations in Metastatic Prostate Cancer.
Marshall CH
J Clin Oncol; 2023 Jun; 41(18):3295-3299. PubMed ID: 37098244
[No Abstract] [Full Text] [Related]
19. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
